Assembly Biosciences announced its full‑year 2025 financial results, reporting revenue of $72.3 million—an increase of 159% from $28.5 million in 2024—while narrowing its net loss to $6.1 million, or $0.55 per share, compared with a $40.2 million loss ($6.69 per share) in 2024. The company’s fourth‑quarter earnings of $2.48 per share beat consensus estimates of $-0.51 (or $-0.86) by a margin of $3.00, and quarterly revenue of $42.47 million surpassed estimates of $7.42 million by $35.05 million. These results demonstrate a dramatic improvement in profitability and cash generation, driven largely by the collaboration with Gilead Sciences.
The earnings release highlighted the licensing of Assembly’s helicase‑primase inhibitor (HPI) program—ABI‑5366 and ABI‑1179—to Gilead following positive Phase 1b data. Gilead declined to exercise or defer its option on ABI‑4334, but the licensing of the HPI candidates has already generated $72.3 million in collaborative research revenue for 2025. The deal validates Assembly’s science and provides a significant cash infusion that underpins the company’s financial performance.
Pipeline progress remains a key focus. ABI‑6250, an oral small‑molecule entry inhibitor for chronic hepatitis delta virus, is advancing toward Phase 2 initiation by the end of 2026, while ABI‑4334, a capsid assembly modulator for chronic hepatitis B, continues in development. These milestones position Assembly to expand its therapeutic portfolio beyond the HPI program.
Cash, cash equivalents, and marketable securities totaled $248.1 million as of December 31 2025, giving the company a strong liquidity buffer that is expected to fund operations through 2028. The combination of robust collaboration revenue and a healthy cash position supports continued investment in research and development.
CEO Jason Okazaki emphasized that “2025 was a pivotal year for the Company, and we anticipate another strong year ahead.” He noted that the Phase 1b data for ABI‑5366 and ABI‑1179 validated Assembly’s science and execution, and highlighted the potential of the company’s oral antivirals to improve patient care. The earnings beat and the Gilead partnership reinforce Assembly’s strategic trajectory and suggest confidence in its long‑term growth prospects.
revised_sentiment_rating
}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.